News & Updates

Metabolic surgery bests medical/lifestyle management for people with diabetes in the long run

21 Jul 2023 by

Individuals with type 2 diabetes (T2D) may fare better with metabolic bariatric surgery, which confers more favourable long-term outcomes as compared with intensive medical and lifestyle management, based on the 7- and 12-year data from the ARMMS-T2D* trial.

Metabolic surgery bests medical/lifestyle management for people with diabetes in the long run

21 Jul 2023

Race, sex, preterm status predict childhood adipokine trajectory

21 Jul 2023

Factors such as preterm status, race, and biological sex are significantly associated with adipokine trajectory throughout childhood, as shown in a study.

Race, sex, preterm status predict childhood adipokine trajectory

21 Jul 2023

Simvastatin plus beta blocker improves survival of cirrhotic patients with variceal bleeding

20 Jul 2023 by

The addition of simvastatin to a nonselective beta blocker results in better survival among cirrhotic patients with variceal bleeding, reports a study presented at EASL 2023.

Simvastatin plus beta blocker improves survival of cirrhotic patients with variceal bleeding

20 Jul 2023

Ketogenic diet reduces weight, raises aldosterone

20 Jul 2023

Adherence to ketogenic diets (KDs) results in weight reduction and increased aldosterone concentrations without worsening cardiometabolic risk factors, suggests a study.

Ketogenic diet reduces weight, raises aldosterone

20 Jul 2023

Oral health screening holds potential for diabetes prevention

20 Jul 2023

Basic indicators of oral health appear to be associated with the risk of developing diabetes, according to a study, suggesting the importance of oral health screening for preventing diabetes.

Oral health screening holds potential for diabetes prevention

20 Jul 2023

Tirzepatide induces weight loss in overweight/obese patients with T2D

20 Jul 2023 by

Treatment with once-weekly tirzepatide, a GIP* and GLP-1** receptor agonist, led to a substantial weight reduction among overweight or obese adults with type 2 diabetes (T2D), according to the phase III SURMOUNT-2 trial presented at ADA 2023.

Tirzepatide induces weight loss in overweight/obese patients with T2D

20 Jul 2023

Tirzepatide bests placebo, other glucose-lowering drugs at keeping lipid levels, waistline in check

19 Jul 2023

Treatment with tirzepatide is associated with better lipid profile and waist circumference outcomes compared with placebo and other glucose-lowering drugs, according to a study.

Tirzepatide bests placebo, other glucose-lowering drugs at keeping lipid levels, waistline in check

19 Jul 2023

Baseline HbA1c strongly predicts metformin failure

19 Jul 2023

Baseline glycated haemoglobin (HbA1c) is the most robust risk factor for metformin failure, reveals a study, noting that routinely available clinical data may be used to identify high-risk patients who may benefit from closer monitoring and earlier treatment intensification.